Valuation: Mabpharm Limited

Market Cap 1.49B 1.74B 221M 189M 176M 162M 305M 21.19B 311M 2.08B 816M 10.6B 831M 813M 35.01B P/E 2024
-8.48x
P/E 2025 44.9x
Enterprise Value 1.7B 1.99B 254M 217M 202M 186M 350M 24.29B 356M 2.39B 935M 12.15B 952M 932M 40.13B EV / Sales 2024
5.06x
EV / Sales 2025 3.2x
Free-Float
22.82%
Yield 2024 *
-
Yield 2025 -
Current month+5.00%
1 month+3.70%
3 months-17.65%
6 months-17.65%
Current year-16.00%
1 week 0.4
Extreme 0.4
0.42
1 month 0.4
Extreme 0.395
0.44
Current year 0.31
Extreme 0.31
0.81
1 year 0.31
Extreme 0.31
0.87
3 years 0.25
Extreme 0.25
0.94
5 years 0.25
Extreme 0.25
1.2
10 years 0.25
Extreme 0.25
1.8
Manager TitleAgeSince
Chief Executive Officer 57 2020-10-27
Corporate Officer/Principal 49 2023-11-30
Corporate Officer/Principal 53 2018-08-02
Director TitleAgeSince
Director/Board Member 57 2018-07-19
Director/Board Member 49 2018-07-19
Chairman 60 2018-07-19
Date Insider Type Main position Quantity % Market Cap.
2/10/23 Other

Director

75,192 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-47.50%-17.65% 221M
-1.90%+2.37%+69.11%+110.88% 73.45B
+0.87%+17.17%+53.05%+95.59% 62.99B
+1.71%-1.44%+2.66%+501.29% 28.05B
-1.40%+4.18%+54.52%+19.60% 25.42B
+21.96%+21.90%+0.51%+2.50% 23.3B
+2.28%+7.98%+42.75%-12.34% 19.45B
0.00%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+17.17%+534.55% 16.53B
+2.39%+5.96%+44.04%+157.77% 13.16B
Average -0.01%+2.47%+48.03%+181.60% 28.07B
Weighted average by Cap. -0.24%+4.38%+57.02%+167.96%

Financials

2024 2025
Net sales 258M 301M 38.43M 32.85M 30.58M 28.19M 52.96M 3.68B 53.94M 362M 142M 1.84B 144M 141M 6.08B 646M 754M 96.15M 82.19M 76.52M 70.54M 132M 9.21B 135M 905M 355M 4.6B 361M 353M 15.21B
Net income -128M -149M -19.04M -16.28M -15.15M -13.97M -26.24M -1.82B -26.73M -179M -70.22M -912M -71.48M -69.93M -3.01B 57.13M 66.66M 8.5M 7.27M 6.77M 6.24M 11.72M 814M 11.93M 80.02M 31.35M 407M 31.92M 31.23M 1.35B
Net Debt 222M 259M 33.07M 28.27M 26.32M 24.26M 45.58M 3.17B 46.42M 311M 122M 1.58B 124M 121M 5.23B 217M 254M 32.36M 27.67M 25.76M 23.74M 44.6M 3.1B 45.43M 305M 119M 1.55B 121M 119M 5.12B
Logo Mabpharm Limited
Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Company’s main products include CMAB009 Enlituo (cetuximab β injection), CMAB007 Aomaishu (Omalizumab α for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Company’s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.
Employees
389
Date Price Change Volume
26-08-19 HK$0.4200 0.00% 50,000
26-08-18 HK$0.4200 +5.00% 24,000
26-08-17 HK$0.4000 -4.76% 176,000
26-08-14 HK$0.4200 0.00% 10,000
26-08-13 HK$0.4200 +2.44% 20,000
  1. Stock Market
  2. Stocks
  3. 2181 Stock